GSK4418959 + PD-1 inhibitor

GSK4418959 + PD-1 inhibitor is an investigational **combination therapy** currently in early clinical development for the treatment of advanced solid tumors, particularly those with **microsatellite instability-high (MSI-H)** genetic profiles such as endometrial, colorectal, rectal, and digestive system cancers[1][2][3][4][5][6][10]. **GSK4418959** (also known as GSK959 or IDE275) is a selective, potent **Werner syndrome helicase (WRN)** inhibitor, designed to exploit synthetic lethality in tumor cells with deficient DNA mismatch repair (MSI-H status), leading to tumor cell death[6][10]. The combination of GSK4418959 with a **PD-1 inhibitor** aims to enhance anti-tumor immune responses: the WRN inhibitor addresses tumor-intrinsic survival pathways, while the **PD-1 inhibitor** releases T-cell mediated immune attack on cancer cells, in line with prevailing immuno-oncology strategies[7][9][10]. The therapy is being evaluated for **safety, pharmacokinetics, and preliminary anti-tumor activity** in a multi-part, dose-escalation Phase 1 study[1][2][3][4][5].